2026-06-19T17:19:00Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88272024-03-16T01:05:27Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

Santos García, Diego Laguna, Ariadna Hernández Vara, Jorge Deus-Fonticoba, Teresa de Cores Bartolomé, Carlos Feal Painceiras, María Íñiguez Alvarado, María Cristina García Díaz, Iago Jesús, Silvia Buongiorno, María Teresa Planellás, Lluis L. Cosgaya, Marina García Caldentey, Juan Caballol, Núria Legarda, Inés Cabo López, Iria López Manzanares, Lydia González Aramburu, Isabel Ávila Rivera, María A. Gómez Mayordomo, Víctor Nogueira, Víctor Puente, Víctor Dotor, Julio Borrue, Carmen Solano Vila, Berta Álvarez Saúco, María Vela Desojo, Lydia Escalante Arroyo, Sonia Cubo Delgado, Esther Carrillo Padilla, Francisco Martínez Castrillo, Juan Carlos Sánchez Alonso, Pilar Alonso Losada, María Gema López Ariztegui, Nuria Gastón, Itziar Kulisevsky Bojarsky, Jaume Menéndez González, Manuel Seijo, Manuel Ruíz Martínez, Javier Valero, Caridad Kurtis, Mónica M. González Ardura, Jessica Alonso Redondo, Rubén Ordás Bandera, Carlos Manuel López Díaz, Luis M. McAfee, Darrian Martínez Martín, Pablo Mir, Pablo COPPADIS Study Group Motor Non-motor symptoms Gender Parkinson’s disease Quality of life Sex Background and objective: Sex plays a role in Parkinson’s disease (PD) mechanisms. We analyzed sex difference manifestations among Spanish patients with PD. Patients and Methods: PD patients who were recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. A cross-sectional and a two-year follow-up analysis were conducted. Univariate analyses and general linear model repeated measure were used. Results: At baseline, data from 681 PD patients (mean age 62.54 ± 8.93) fit the criteria for analysis. Of them, 410 (60.2%) were males and 271 (39.8%) females. There were no differences between the groups in mean age (62.36 ± 8.73 vs. 62.8 ± 9.24; p = 0.297) or in the time from symptoms onset (5.66 ± 4.65 vs. 5.21 ± 4.11; p = 0.259). Symptoms such as depression (p < 0.0001), fatigue (p < 0.0001), and pain (p < 0.00001) were more frequent and/or severe in females, whereas other symptoms such as hypomimia (p < 0.0001), speech problems (p < 0.0001), rigidity (p < 0.0001), and hypersexuality (p < 0.0001) were more noted in males. Women received a lower levodopa equivalent daily dose (p = 0.002). Perception of quality of life was generally worse in females (PDQ-39, p = 0.002; EUROHIS-QOL8, p = 0.009). After the two-year follow-up, the NMS burden (Non-Motor Symptoms Scale total score) increased more significantly in males (p = 0.012) but the functional capacity (Schwab and England Activities of Daily Living Scale) was more impaired in females (p = 0.001). Conclusion: The present study demonstrates that there are important sex differences in PD. Long-term prospective comparative studies are needed. 2024-03-15 2024-03-15 2023-02 info:eu-repo/semantics/article http://hdl.handle.net/10259/8827 10.3390/jcm12041329 2077-0383 eng Journal of Clinical Medicine. 2023, V. 12, n. 4, 1329 https://doi.org/10.3390/jcm12041329 http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Atribución 4.0 Internacional MDPI